Liyuan Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Liyuan Liu has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Binggen Li
R&D Department Weihai Zhengsheng Biotechnology Co., Ltd Weihai China
1 shared publication - Chengyun Zheng
Department of Hematology, The Second Qilu Hospital of Shandong University, Jinan, Shandong, China
1 shared publication - Chenliu Fan
Department of Hematology The Second Hospital of Shandong University Jinan Shandong China
1 shared publication - Chenxi Sun
Department of Hematology The Second Hospital of Shandong University Jinan Shandong China
1 shared publication - Dexiao Kong
Department of Hematology The Second Hospital of Shandong University Jinan Shandong China
1 shared publication - Xiaoli Feng
Department of Clinical Laboratory The Second Hospital of Shandong University Jinan Shandong China
1 shared publication
Latest Publications
- 27 August 2024
- Published by Wiley in The FASEB Journal
- Vol. 38 (16) , e70024
PDCD4 interacting with PIK3CB and CTSZ promotes the apoptosis of multiple myeloma cells
The role of programmed cell death 4 (PDCD4) in multiple myeloma (MM) development remains unknown. Here, we investigated its role and action mechanism in MM. Bioinformatic analysis indicated that patients with MM and high PDCD4 expression had higher overall survival than those with low PDCD4 expression. PDCD4 expression promoted MM cell apoptosis and inhibited their viability in vitro and tumor growth in vivo. RNA‐binding protein immunoprecipitation sequencing analysis showed that PDCD4 is bound to the 5′ UTR of the apoptosis‐related genes PIK3CB , Cathepsin Z ( CTSZ ), and X‐chromosome‐linked apoptosis inhibitor ( XIAP ). PDCD4 knockdown reduced the cell apoptosis rate, which was rescued by adding PIK3CB, CTSZ, or XIAP inhibitors. Dual luciferase reporter assays confirmed the internal ribosome entry site (IRES) activity of the 5′ UTRs of PIK3CB and CTSZ . An RNA pull‐down assay confirmed binding of the 5′ UTR of PIK3CB and CTSZ to PDCD4, identifying the specific binding fragments. PDCD4 is expected to promote MM cell apoptosis by binding to the IRES domain in the 5′ UTR of PIK3CB and CTSZ and inhibiting their translation. Our findings suggest that PDCD4 plays an important role in MM development by regulating the expression of P IK3CB , CTSZ, and XIAP , and highlight new potential molecular targets for MM treatment.
- 27 August 2024
- Published by Wiley in The FASEB Journal
- Vol. 38 (16) , e70024
PDCD4 interacting with PIK3CB and CTSZ promotes the apoptosis of multiple myeloma cells
The role of programmed cell death 4 (PDCD4) in multiple myeloma (MM) development remains unknown. Here, we investigated its role and action mechanism in MM. Bioinformatic analysis indicated that patients with MM and high PDCD4 expression had higher overall survival than those with low PDCD4 expression. PDCD4 expression promoted MM cell apoptosis and inhibited their viability in vitro and tumor growth in vivo. RNA‐binding protein immunoprecipitation sequencing analysis showed that PDCD4 is bound to the 5′ UTR of the apoptosis‐related genes PIK3CB , Cathepsin Z ( CTSZ ), and X‐chromosome‐linked apoptosis inhibitor ( XIAP ). PDCD4 knockdown reduced the cell apoptosis rate, which was rescued by adding PIK3CB, CTSZ, or XIAP inhibitors. Dual luciferase reporter assays confirmed the internal ribosome entry site (IRES) activity of the 5′ UTRs of PIK3CB and CTSZ . An RNA pull‐down assay confirmed binding of the 5′ UTR of PIK3CB and CTSZ to PDCD4, identifying the specific binding fragments. PDCD4 is expected to promote MM cell apoptosis by binding to the IRES domain in the 5′ UTR of PIK3CB and CTSZ and inhibiting their translation. Our findings suggest that PDCD4 plays an important role in MM development by regulating the expression of P IK3CB , CTSZ, and XIAP , and highlight new potential molecular targets for MM treatment.